Technical Specifications
| Specification | Details |
|---|---|
| Product Name | Retatrutide |
| Chemical Classification | Synthetic Peptide |
| Peptide Type | GIP / GLP-1 / Glucagon Receptor Agonist |
| Chemical Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | Approximately 4731.4 g/mol |
| CAS Number | 2381089-83-2 |
| Form | Lyophilized Research Material |
| Strength Options | Refer to product-specific listing |
| Purity | Refer to batch-specific CoA |
| Intended Use | Laboratory Research Only |
Product Overview
Retatrutide is an investigational synthetic peptide designed to interact with three metabolic hormone receptors: GIP, GLP-1, and glucagon receptors. Its multi-receptor activity makes it a research compound of interest in studies involving peptide pharmacology, receptor signaling, and metabolic biology.
Retatrutide is relevant to controlled laboratory investigations involving GIP, GLP-1, and glucagon receptor biology, peptide-receptor interactions, cellular signaling, endocrine research, and comparative metabolic pathway studies.
This research material is supplied in a lyophilized format for qualified laboratory researchers conducting controlled experimental work.
Laboratory Applications
Retatrutide may be investigated in laboratory settings involving:
- GIP receptor research
- GLP-1 receptor research
- Glucagon receptor research
- Multi-receptor peptide studies
- Peptide-receptor interaction research
- Receptor pharmacology
- Cellular signaling studies
- Metabolic pathway research
- Endocrine research
- Peptide structure-function studies
- Biochemical assay development
- Molecular biology
- Comparative incretin research
Product Characteristics
Triple-Target Peptide
Retatrutide is characterized by activity at GIP, GLP-1, and glucagon receptors, making it relevant to laboratory research examining multi-receptor signaling pathways.
Investigational Research Compound
Retatrutide remains an investigational compound and is being studied for its pharmacological and metabolic characteristics. Its research status should not be interpreted as regulatory approval for therapeutic use.
Lyophilized Research Material
Supplied as a lyophilized material intended for laboratory research applications. Product identity, purity, and analytical characteristics should be verified against the applicable batch-specific documentation.
Handling & Storage
- Store according to the manufacturer’s recommended conditions.
- Protect from excessive heat, direct sunlight, and moisture.
- Keep the container tightly closed when not in use.
- Minimize unnecessary exposure to environmental conditions.
- Follow all batch-specific storage instructions.
- Consult the applicable Safety Data Sheet (SDS) before handling.
- Laboratory personnel should follow appropriate institutional handling and safety procedures.
Product Features
✓ Retatrutide
✓ Synthetic Peptide
✓ GIP / GLP-1 / Glucagon Receptor Research
✓ Triple-Receptor Research Compound
✓ Lyophilized Research Material
✓ Suitable for Peptide Research
✓ Receptor Pharmacology Research
✓ Cellular Signaling Research
✓ Metabolic Research
✓ Batch-Specific CoA Available
✓ Research Use Only
Important Notice
This product is offered strictly as a laboratory research material.
It is not intended for human or veterinary administration, self-administration, diagnosis, treatment, cure, or prevention of any disease or medical condition.
Retatrutide is an investigational compound and is not FDA-approved. This research material should not be represented as an FDA-approved drug, pharmaceutical product, or equivalent to an approved medication.
No therapeutic, weight-management, blood-glucose, or other medical claims should be inferred from the research information presented on this page.
The exact identity, purity, stability, and analytical specifications of the supplied material should be verified against the applicable batch Certificate of Analysis (CoA) and manufacturer documentation.
Always consult the product-specific Safety Data Sheet (SDS) and follow appropriate laboratory procedures.






Reviews
There are no reviews yet.